The odds that DeRosa would have an OPS of

106, or fax, 1-972-934-2870,, for Pizza Patron. Some reports suggest that if the Giants sign Mark DeRosa, they plan to play him largely in left field. This would be a probably stupid idea.DeRosa has value at third, not as a corner outfielder. DeRosa’s OPS numbers the last three seasons were .791, .857 and .752. The first two of those seasons were performed playing in Wrigley Field half of the time. Wrigley is a great place to hit. Even last year split between St. Louis and Cleveland, DeRosa played in better hitters’ parks than he’ll play in in San Francisco.The odds that DeRosa would have an OPS of .800 over a full season in either 2010 or 2011 playing his home games in San Francisco is extremely slim. Even an .800 OPS really isn’t good enough from your players playing in left field. Without the DH, National League teams in particular need to get as much offense as possible out of the left field slot. There’s no way DeRosa will cut it.The same is true for first base. DeRosa only has value playing 3B and 2B, and other positions as necessitated by injuries.As bad as the Giants’ offense was last year, it won’t be any better in 2010 with DeRosa starting regularly in left field. This article is also featured on BOSTON(Business Wire)On December 31, 2008, H&Q Life Sciences Investors paid a quarterly stockdistribution of $0.26 per share. Of this distribution, $0.073 is estimated to bederived from long-term capital gains and $0.187 from paid in capital. Thecomposition of this and subsequent distributions may vary from quarter toquarter because it may be materially impacted by future realized gains andlosses on securities.

The aggregate of the net unrealized depreciation ofportfolio securities and undistributed net realized losses on the sale ofsecurities is $58,580,672, of which $51,409,596 represents net unrealizeddepreciation of portfolio securities. The Fund currently estimates that it has distributed more than its income andrealized capital gains; therefore, a portion of this distribution may be areturn of capital. A return of capital distribution does not necessarily reflectthe Funds investment performance and should not be confused with "yield" or"income." The amounts and sources of distributions reported in this notice are onlyestimates and are not being provided for tax reporting purposes. The actualamounts and sources of the amounts for tax reporting purposes will depend uponthe Funds investment experience during the remainder of its fiscal year endingSeptember 30, 2009, and may be subject to changes based on the tax regulations.Shareholders will receive a Form 1099-DIV in early 2009 notifying them of thesources of all distributions for calendar year 2008 for federal income taxpurposes. H&Q Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests inpublic and private companies in the life sciences industry.

Hambrecht & QuistCapital Management LLC, based in Boston, serves as Investment Adviser to theFund. Shares of the Fund can be purchased on the New York Stock Exchange throughany securities broker. For additional information, please visit or call (617) 772-8500. H&Q Life Sciences Investors617-772-8500 Business Wire 2009. New surgeries and a study by JAMA confirm there are more options for patients.MILWAUKEE, Jan. 5 /PRNewswire/ One in ten people will suffer from aseizure in their life and many of those will be diagnosed with epilepsy.Medication will help approximately two-thirds of the people with epilepsy, butmany continue to have seizures, even though there are other alternatives."Epilepsy ended my teaching career," says Mary Catanzaro a former Englishlecturer at Marquette University."I would have seizures in front of mystudents and never know that they had happened."Catanzaro suffered from complex partial seizures.These seizures, whilenot as recognizable as the "shaking" seizures of the movies, are common.InCatanzaro's case one of these episodes left her with third-degree burns aftershe placed her hand on a hot frying pan."For 20 years I tried different pharmaceuticals," says Catanzaro."When anew drug came out, my doctor was handing me a prescription, but it neverworked."The average patient waits 20 years before taking the next step and hassurgery.Temporal lobectomies cure many epilepsy cases but factors limitpatients from taking advantage of this option."Many people are scared by brain surgery, and that is understandable, butit keeps them from treatment for far too long," says Dr George Morris, anepileptologist at Aurora St. Luke's Medical Center in Milwaukee."Anotherdifficulty is that only specialized neurosurgeons perform this procedure.Many patients rely on their physician to refer them to the best course ofaction, and they never learn about the successes we are having with temporallobectomies."Approximately one-third of the affected population will not respond topharmaceutical treatments for epilepsy, according to Dr.

Morris.Those samepeople do have another option.Surgically we can remove a small section oftheir temporal lobe and stop or minimize their seizures.Better than four outof every five surgical patients will see either significant success or seetheir epilepsy cured.In December, the Journal of the American Medical Association published astudy that recommends that surgery should be considered more quickly to treatpatients with epilepsy.The conclusion of the JAMA study concludes that theaverage patient will experience substantial gains in life expectancy andquality of life from these surgeries.According to Dr. Morris a temporal lobectomy has been shown to be as safeas any other general surgery.Additionally, patients' IQ testing aftersurgery has shown no changes and most return to work within six weeks.Today Catanzaro works from home and contributes to many scholarly books."It took me about 5 years to realize that I was cured," says Catanzaro."I was always waiting for the next seizure, but now the waiting and the fearare over."Aurora Health Care is a not-for-profit Wisconsin health care provider anda national leader in efforts to improve the quality of care.Aurora providescare at sites in more than 90 communities throughout eastern Wisconsin. http:// Health CareAdam V. Beeson of Aurora Health Care, 1-414-649-3915, . CALGARY, Alberta, Jan 5 (Reuters) - TransAlta Corp (TA.TO)said on Monday its C$170 million ($143 million) Kent Hills windfarm in New Brunswick has begun operating, producing up to 96megawatts of power for Canada's biggest investor-owned powercompany. Stocks TransAlta said the facility uses 32 3-megawatt windgenerators to produce electricity at the Kent Hills site, 30kilometers (19 miles) southwest of Moncton, New Brunswick, andwill produce enough power for 17,300 homes. The Calgary-based company has said the Kent Hills wind farmcan be further expanded to add an additional 54 megawatts ofpower. TransAlta now has 248 megawatts of wind-powered generationand a total generating capacity of 8,788 megawatts from 50facilities in North America and Australia.